Charles J. Ryan

Active 2004–2026

107
Papers
24,806
Citations
63
h-index
103
i10-index

Citations

Citations per year for Charles J. Ryan1994: 2 citations1995: 1 citations2004: 2 citations2005: 6 citations2006: 13 citations2007: 9 citations2008: 24 citations2009: 29 citations2010: 52 citations2011: 136 citations2012: 138 citations2013: 231 citations2014: 212 citations2015: 226 citations2016: 220 citations2017: 233 citations2018: 306 citations2019: 899 citations2020: 982 citations2021: 1,189 citations2022: 840 citations2023: 667 citations2024: 1,145 citations2025: 514 citations2026: 13 citations1996–2003: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,754 citing papers, 26.4% of this breakdownUnited Kingdom: 760 citing papers, 7.3% of this breakdownChina: 722 citing papers, 6.9% of this breakdownCanada: 629 citing papers, 6% of this breakdownGermany: 584 citing papers, 5.6% of this breakdownItaly: 567 citing papers, 5.4% of this breakdownFrance: 436 citing papers, 4.2% of this breakdownAustralia: 411 citing papers, 3.9% of this breakdownSpain: 329 citing papers, 3.2% of this breakdownNetherlands: 306 citing papers, 2.9% of this breakdownSwitzerland: 268 citing papers, 2.6% of this breakdownJapan: 259 citing papers, 2.5% of this breakdown
0%26.4%Other 23.1%

Fields

  • Medicine75.5%
  • Biochemistry, Genetics and Molecular Biology17.1%
  • Immunology and Microbiology2.8%
  • Materials Science1.1%
  • Computer Science0.6%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • Other2.4%

Topics

  • Prostate Cancer Treatment and Research21%
  • Prostate Cancer Diagnosis and Treatment10%
  • Radiopharmaceutical Chemistry and Applications5.7%
  • Cancer, Lipids, and Metabolism3.5%
  • Cancer Genomics and Diagnostics3.1%
  • PARP inhibition in cancer therapy2.9%
  • Other53.8%

Coauthors

All papers

Open in search
  1. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter S. Nelson, Lawrence H. Schwartz, Susan Halabi, Philip W. Kantoff, Andrew J. Armstrong - Journal of Clinical Oncology 2016 cited by 1,603

  2. Abiraterone and Increased Survival in Metastatic Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christopher M. Haqq, Howard I. Scher - New England Journal of Medicine 2011 cited by 4,394

  3. Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 414

  4. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eric J. Small - Journal of Clinical Oncology 2018 cited by 812

  5. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jonathan Chou, Haolong Li, Rajdeep Das, Hui Li, Ruhollah Moussavi-Baygi, Hani Goodarzi, Luke A. Gilbert, Primo N. Lara, Christopher P. Evans, Theodore C. Goldstein, Joshua M. Stuart, Scott A. Tomlins, Daniel E. Spratt, R. Keira Cheetham, Donavan T. Cheng, Kyle Kai‐How Farh, Julian Gehring, Jörg Hakenberg, Arnold Liao, Philip G. Febbo, John Shon, Brad Sickler, Serafim Batzoglou, Karen E. Knudsen, Housheng Hansen He, Jiaoti Huang, Alexander W. Wyatt, Scott M. Dehm, Alan Ashworth, Arul M. Chinnaiyan, Christopher A. Maher, Eric J. Small, Felix Y. Feng - Cell 2018 cited by 759

  6. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thomas W. Griffin, Howard I. Scher, Dana E. Rathkopf - New England Journal of Medicine 2012 cited by 2,795

  7. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 cited by 1,354

  8. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring aBRCA1orBRCA2Gene Alteration

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 678

  9. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Ross Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Amee Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Journal of Cancer 2023 cited by 157

  10. Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms

    Authors: , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2021 cited by 194

  11. Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , - Clinical Cancer Research 2013 cited by 466

  12. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer

    Authors: , , , , , , , , , , , , , , , - JAMA Oncology 2018 cited by 253

  13. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 cited by 393

  14. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2023 cited by 97

  15. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Rosalind A. Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Daniel J. George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia S. Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz‐Amit, Christopher J. Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Alicia K. Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Urology 2022 cited by 118

  16. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jacqueline Powers, Raoul S. Concepcion, Daniel W. Lin, Richard C. Wender, James Ryan Mark, Anthony J. Costello, Arthur L. Burnett, Oliver Sartor, William B. Isaacs, Jianfeng Xu, Jeffrey N. Weitzel, Gerald L. Andriole, Himisha Beltran, Alberto Briganti, Lindsey Byrne, Anne Calvaresi, Thenappan Chandrasekar, David Y.T. Chen, Robert B. Den, Albert Dobi, E. David Crawford, James A. Eastham, Scott E. Eggener, Matthew L. Freedman, Marc B. Garnick, Patrick T. Gomella, Nathan Handley, Mark Hurwitz, Joseph K. Izes, R. Jeffrey Karnes, Costas D. Lallas, Lucia R. Languino, Stacy Loeb, Ana María López, Kevin R. Loughlin, Grace Lu‐Yao, S. Bruce Malkowicz, Mark Mann, Patrick Mille, Martin Miner, Todd M. Morgan, José Moreno, Lorelei A. Mucci, Ronald E. Myers, Sarah M. Nielsen, Brock O’Neil, Wayne H. Pinover, Peter A. Pinto, Wendy Poage, Ganesh V. Raj, Timothy R. Rebbeck, Charles J. Ryan, Howard M. Sandler, Matthew J. Schiewer, Emily Scott, Brittany M. Szymaniak, William Tester, Edouard J. Trabulsi, Neha Vapiwala, Evan Y. Yu, Charnita Zeigler‐Johnson, Leonard G. Gomella - Journal of Clinical Oncology 2020 cited by 279

  17. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2017 cited by 268

  18. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gero Kramer, Chris Logothetis, Fernando Cotait Maluf, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Vedang Murthy, William Oh, Piet Ost, Anwar R. Padhani, Chris Parker, Colin C. Pritchard, Mack Roach, Mark A. Rubin, Charles J. Ryan, Fred Saad, Oliver Sartor, Howard I. Scher, Avishay Sella, Neal D. Shore, Matthew R. Smith, Howard R. Soule, Cora N. Sternberg, Hiroyoshi Suzuki, Christopher J. Sweeney, Matthew R. Sydes, Ian F. Tannock, Bertrand Tombal, R. Valdagni, Thomas Wiegel, Aurelius Omlin - European Urology 2017 cited by 643

  19. Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Joshua M. Stuart, George Thomas, Felix Y. Feng, Eric J. Small, Joel A. Yates, Zheng Xia, Joshi J. Alumkal - Nature Communications 2022 cited by 59

  20. NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo

    Authors: , , , , , , , , , , , , , - Cancers 2020 cited by 95

  21. 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience

    Authors: , , , , , , , , - Journal of Nuclear Medicine 2016 cited by 212

  22. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Zheng Xia - National Academy of Sciences, Proceedings of the National Academy of Sciences 2020 cited by 169

  23. Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States

    Authors: , , , , , , , , , , , - The Journal of Urology 2021 cited by 57

  24. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philip W. Kantoff, Raja B. Khauli, Raya Leibowitz‐Amit, Chris Logothetis, Fernando Cotait Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind M’rabti, Declan G. Murphy, Vedang Murthy, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Chris Parker, Darren M.C. Poon, Colin C. Pritchard, Robert E. Reiter, Mack Roach, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Neal D. Shore, Eric J. Small, Matthew R. Smith, Howard R. Soule, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Christopher J. Sweeney, Matthew R. Sydes, Mary-Ellen Taplin, Bertrand Tombal, Levent Türkeri, Inge M. van Oort, A. Zapatero, Aurelius Omlin - European Urology 2020 cited by 395